返回 
加入收藏
依达拉奉右莰醇与复方脑肽节苷脂治疗急性缺血性脑卒中的疗效、安全性和经济性
x
请在关注微信后，向客服人员索取文件
| 篇名： | 依达拉奉右莰醇与复方脑肽节苷脂治疗急性缺血性脑卒中的疗效、安全性和经济性 |
| TITLE： | Efficacy，safety and cost-effectiveness of edaravone dexborneol and compound porcine cerebroside ganglioside in the treatment of acute ischemic stroke |
| 摘要： | 目的 评价依达拉奉右莰醇与复方脑肽节苷脂治疗急性缺血性脑卒中的疗效、安全性和经济性，为临床治疗选择提供决策参考。方法收集2021年1月－2021年12月住院治疗的488例急性缺血性脑卒中患者的病历资料，根据治疗方案分为两组，其中依达拉奉右莰醇组268例，复方脑肽节苷脂组220例。应用倾向性评分匹配法平衡两组基线水平后，依据治疗前后美国国立卫生研究院卒中量表（NIHSS）评分的变化情况评定疗效；从医院不良反应上报系统中收集患者的不良反应发生情况；从中国卫生体系角度出发，分析两种方案的经济性，并进行单因素敏感性分析。结果倾向性评分匹配后，依达拉奉右莰醇组和复方脑肽节苷脂组各纳入患者125例，有效率分别为81.6%和74.4%，疗效无显著性差异，成本平均值分别为13560.30元和14958.68元，依达拉奉右莰醇组的成本更低。两组均未检索到不良反应上报信息。单因素敏感性分析结果显示，复方脑肽节苷脂组的其他药品费为较为敏感的参数。结论依达拉奉右莰醇与复方脑肽节苷脂治疗急性缺血性脑卒中的短期疗效和安全性相当，但依达拉奉右莰醇方案的成本更低，是更为经济的方案。 |
| ABSTRACT： | OBJECTIVE To evaluate efficacy， safety and cost-effectiveness of edaravone dexborneol and compound porcine cerebroside ganglioside in the treatment of acute ischemic stroke， and to provide decision-making reference for clinical treatment selection. METHODS The medical records of 488 patients with acute ischemic stroke hospitalized from Jan. 2021 to Dec. 2021 were collected and divided into two groups according to the treatment plan， i.e. 268 patients in edaravone dexborneol group， and 220 patients in compound porcine cerebroside ganglioside group. After baseline levels of the two groups were balanced using propensity score matching method， curative effect was evaluated according to the changes of NIHSS scores before and after treatment； the occurrence of adverse drug reactions in patients were collected from the hospital adverse reaction reporting system； from the perspective of China’s health system， the cost-effectiveness of the two options were analyzed， and one-way sensitivity analysis was conducted. RESULTS After the propensity score matching， 125 patients were included in the edaravone dexborneol group and compound porcine cerebroside ganglioside group， respectively. The response rates were 81.6% and 74.4%， respectively， with no significant difference. The average costs were 13 560.30 yuan and 14 958.68 yuan， respectively； the cost of edaravone dexborneol group was lower than that of compound porcine cerebroside ganglioside group. No adverse reaction reporting information was retrieved in both groups. Results of one-way sensitivity analysis showed that other drug costs in compound porcine cerebroside ganglioside group was relatively sensitive parameters. CONCLUSIONS Short-term efficacy and safety of edaravone dexborneol are equivalent to those of compound porcine cerebroside ganglioside in treating acute ischemic stroke. But edaravone dexborneol regimen had lower cost and is a more economical scheme. |
| 期刊： | 2023年第34卷第08期 |
| 作者： | 李龙；王彬；曲政；黄俊荣 |
| AUTHORS： | LI Long，WANG Bin，QU Zheng，HUANG Junrong |
| 关键字： | 依达拉奉右莰醇；复方脑肽节苷脂；神经保护剂；缺血性脑卒中；有效性；安全性；经济性；最小成本分析 |
| KEYWORDS： | edaravone dexborneol； compound porcine cerebroside ganglioside； neuroprotective agent； ischemic stroke； efficacy； |
| 阅读数： | 141 次 |
| 本月下载数： | 3 次 |
* 注：未经本站明确许可，任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作！
